
Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB, reported additional interim results from its ongoing phase I/II clinical study of its ChronVac-CŪ therapeutic DNA vaccine, which is delivered using Inovio's electroporation-based DNA delivery system.
Click here for full Story http://www.medicalnewstoday.com/articles/113964.php |